High-density lipoprotein subclass and particle size in coronary heart disease patients with or without diabetes

Lipids in Health and Disease

Volumn 11, Issue , 2012, Pages

  Tian, Li ^a,b   Long, Shiyin ^a,c   Li, Chuanwei ^a   Liu, Yinghui ^a,b   Chen, Yucheng ^a   Zeng, Zhi ^a   Fu, Mingde ^a,b  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

^c UNIVERSITY OF SOUTH CHINA   (China)

Author keywords

Coronary heart disease; Diabetic mellitus; Fasting plasma glucose; High density lipoprotein subclasses

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIURETIC AGENT; GLUCOSE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; DIET RESTRICTION; FEMALE; GEL ELECTROPHORESIS; GLUCOSE BLOOD LEVEL; HUMAN; IMMUNODETECTION; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PARTICLE SIZE;

AGED; APOLIPOPROTEINS; CORONARY DISEASE; DIABETES MELLITUS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; HUMANS; LIPIDS; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PARTICLE SIZE; REGRESSION ANALYSIS;

EID: 84860914340     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-11-54     Document Type: Article

References (43)

1. Diabetes as a risk factor for myocardial infarction: population and gender perspectives. Lundberg V, Stegmayr B, Asplund K, Eliasson M, Huhtasaari F, J Intern Med 1997 241 485 492 10497624
2. Diabetes and all-cause and coronary heart disease mortality among US male physicians. Lotufo PA, Gaziano JM, Chae CU, Ajani UA, Moreno-John G, Buring JE, Manson JE, Arch Intern Med 2001 161 242 247 10.1001/archinte.161.2.242 11176738
3. Sex differences in the impact of coexistent diabetes on survival in patients with coronary heart disease. Liao Y, Cooper RS, Ghali JK, Lansky D, Cao G, Lee J, Diabetes Care 1993 16 708 713 10.2337/diacare.16.5.708 8495609
4. The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20years of follow-up. Hu FB, Stampfer MJ, Solomon CG, Liu S, Willett WC, Speizer FE, Nathan DM, Manson JE, Arch Intern Med 2001 161 1717 1723 10.1001/archinte.161.14.1717 11485504
5. Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study. Kannel WB, McGee DL, Diabetes Care 1979 2 120 126 10.2337/diacare.2.2.120 520114
6. Impact of diabetes on mortality after the first myocardial infarction. Miettinen H, Lehto S, Salomaa V, Mhnen M, Niemel M, Haffner SM, Pyörälä K, Tuomilehto J, The FINMONICA Myocardial Infarction Register Study Group, Diabetes Care 1998 21 69 75 10.2337/diacare.21.1.69 9538972
7. Diabetic dyslipidaemia. Betteridge DJ, Eur Clin Invest 1999 29 Suppl 2 12 16
8. Hypoalphalipoproteinemia (low high density lipoprotein) as a risk factor for coronary heart disease. Vega GL, Grundy SM, Curr Opin Lipidol 1996 7 209 216 10.1097/00041433-199608000-00007 8883496
9. HDL metabolism and the role of HDL in the treatment of high-risk patients with cardiovascular disease. Brewer HB, Curr Cardiol Rep 2007 9 486 492 10.1007/BF02938393 17999874
10. Value of high density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL Intervention Trial. Asztalos BF, Collins D, Cupples LA, Demissie S, Horvath KV, Bloomfield HE, Robins SJ, Schaefer EJ, Arterioscler Thromb Vasc Biol 2005 25 2185 2191 10.1161/01.ATV.0000183727.90611.4f 16123324
11. Relation of Increased Prebeta-1 High-Density Lipoprotein Levels to Risk of Coronary Heart Disease. Guey LT, Pullinger CR, Ishida BY, OConnor PM, Zellner C, Francone OL, Laramie JM, Naya-Vigne JM, Siradze KA, Deedwania P, Redberg RF, Frost PH, Seymour AB, Kane JP, Malloy MJ, Am J Cardiol 2011 108 360 366 10.1016/j.amjcard.2011.03.054 21757044
12. HDL particle size and the risk of coronary heart disease in apparently healthy men and women: the EPIC-Norfolk prospective population study. Arsenault BJ, Lemieux I, Despres JP, Gagnon P, Wareham NJ, Stroes ES, Kastelein JJ, Khaw KT, Boekholdt SM, Atherosclerosis 2009 206 276 281 10.1016/j.atherosclerosis. 2009.01.044 19268944
13. Particle size and Concentration Determined by Nuclear Magnetic Resonance. Garvey WT, Kwon S, Zheng DY, Shaughnessy S, Wallace P, Hutto A, Pugh K, Jenkins AJ, Klein RL, Liao YL, Diabetes 2003 52 453 462 12540621
14. Functional assessment of HDL: moving beyond static measures for risk assessment. Rosenson RS, Cardiovasc Drugs Ther 2010 24 71 75 10.1007/s10557-009-6214-3 20094763
15. A more meaningful scoring system for determining the severity of coronary heart disease. Gensini GG, Am J Cardiol 1983 51 606 607 10.1016/S0002-9149(83) 80105-2 6823874
16. WHO, Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes metlitus WHO, Geneva 1999 Available at: http://www.staff.ncl.ac.uk/philip.home/who dmg.pdf. Accessible in Jan 2007
17. Nondenaturing polyacrylamide gradient gel electrophoresis. Nichols AV, Krauss RM, Musliner TA, Methods Enzymol 1986 128 417 431 3724517
18. Development of a proton nuclear magnetic resonance spectroscopic method for determining plasma lipoprotein concentrations and subspecies distributions from a single, rapid measurement. Otvos JD, Jeyarajah EJ, Bennett DW, Krauss RM, Clin Chem 1992 38 1632 1638 1326420
19. Early incorporation of cell-derived cholesterol into pre-migrating high density lipoprotein. Castro GR, Fielding CJ, Biochemistry 1988 27 25 29 10.1021/bi00401a005 3126809
20. Molecular physiology of reverse cholesterol transport. Fielding CJ, Fielding PE, J Lipid Res 1995 36 211 228 7751809
21. Alterations of HDL subclasses in hyperlipidemia. Xu YH, Fu MD, Clin Chim Acta 2003 332 95 102 10.1016/S0009-8981(03)00138-4 12763286
22. Alterations of high density lipoprotein subclasses in obese subjects. Tian L, Jia LQ, Fu MD, Tian Y, Xu YH, Tian HM, Yang YY, Lipids 2006 41 789 796 10.1007/s11745-006-5032-7 17120933
23. Alterations of HDL subclasses in endogenous hypertriglyceridemia. Gou LT, Fu MD, Xu YH, Tian Y, Yan BY, Yang LC, Am Heart J 2005 150 1039 1045 10.1016/j.ahj.2005.02.032 16290993
24. Alterations of high-density lipoprotein subclasses in hypercholesterolemia and combined hyperlipidemia. Jia LQ, Fu MD, Tian Y, Xu YH, Gou LT, Tian HM, Tian LI, Int J Cardio 2007 120 331 337 10.1016/j.ijcard.2006. 10.007
25. WHO, Technical Report Series No. 844. Prevention of diabetes mellitus: report of a WHO Study Group World Health Organization, Geneva 1994
26. Study on the content of serum HDL subclasses in type 2 diabetic patients. Xu YH, Fu MD, Wu XW, Ren Y, Chin J Diabetes 2001 9 160 162
27. Relationship between the concentrations of plasma lipids and the contents of serum HDL subclasses in patients with coronary heart disease. Xu YH, Fu MD, Xu YX, Yang LC, Liu Y, Yao J, J Clin Cardiol (China) 2003 19 581 584
28. Triglyceride enrichment of HDL enhances in vivo metabolic clearance of HDL apo A-I in healthy men. Lamarche B, Uffelman KD, Carpentier A, Cohn JS, Steiner G, Barrett PH, Lewis GF, J Clin Invest 1999 103 1191 1199 10.1172/JCI5286 10207171
29. Lipoprotein lipase. A multifunctional enzyme relevant to common metabolic diseases. Eckel RH, N Engl J Med 1989 320 1060 1068 10.1056/NEJM198904203201607 2648155
30. Formation and metabolism of prebeta migrating, lipid-poor apolipoprotein A-I. Rye KA, Barter PJ, Arterioscler Thromb Vasc Biol 2004 24 421 428 10.1161/01.ATV.0000104029.74961.f5 14592845
31. ATP-binding cassette transporter G1 and lipid homeostasis. Baldan A, Tarr P, Lee R, Edwards PA, Curr Opin Lipidol 2006 17 227 232 10.1097/01.mol. 0000226113.89812.bb 16680026
32. Remodelling of high density lipoproteins by plasma factors. Rye K-A, Clay MA, Barter PJ, Atherosclerosis 1999 145 227 238 10.1016/S0021-9150(99)00150-1 10488948
33. Studies on the plasma lipid profiles, and LCAT and CETP activities according to hyperlipoproteinemia phenotypes(HLP). Lee M, Kim JQ, Kim J, Oh H, Park M, Atherosclerosis 2001 159 381 389 10.1016/S0021-9150(01)00513-5 11730818
34. Changes of lipolytic enzymes cluster with insulin resistance syndrome. Botnia Study Group. Knudsen P, Eriksson J, Lahdenpera S, Kahri J, Groop L, Taskinen MR, Diabetologia 1995 38 344 350 10.1007/BF00400640 7758882
35. Reduction in ABCG1 in Type 2 diabetic mice increases macrophage foam cell formation. Mauldin JP, Srinivasan S, Mulya A, Gebre A, Parks JS, Daugherty A, Hedrick CC, J Biol Chem 2006 281 21216 21224 10.1074/jbc.M510952200 16723355
36. Polyunsaturated fatty acids and acetoacetate downregulate the expression of the ATP-binding cassette transporter A1. Uehara Y, Engel T, Li Z, Goepfert C, Rust S, Zhou X, Langer C, Schachtrup C, Wiekowski J, Lorkowski S, Assmann G, von Eckardstein A, Diabetes 2002 51 2922 2928 10.2337/diabetes.51.10.2922 12351428
37. Human plasma phospholipid transfer protein causes high density lipoprotein conversion. Jauhiainen M, Metso J, Pahlman R, Blomqvist S, van Tol A, Ehnholm C, J Biol Chem 1993 268 4032 4036 8440695
38. Lipoprotein distribution and composition in obesity: their association with central adiposity. James RW, Brulhart-Meynet MC, Lehmann T, Golay A, Int J Obes 1997 21 1115 1120 10.1038/sj.ijo.0800524
39. Regional adiposity patterns in relation to lipids, lipoprotein cholesterol, and lipoprotein subfraction mass in men. Terry RB, Wood PD, Haskell WL, Stefanick ML, Krauss RM, J Clin Endocrinol Metab 1989 68 191 199 10.1210/jcem-68-1-191 2909551
40. Body fat distribution, rather than overall adiposity, influences serum lipids and lipoproteins in men independently of age. Walton C, Lees B, Grook D, Worthington M, Godsland IF, Stevenson JC, Am J Med 1995 99 459 464 10.1016/S0002-9343(99)80220-4 7485201
41. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001 285 2486 2497 10.1001/jama.285.19.2486 11368702
42. Distribution of ApoA-I-containing HDL subpopulations in patients with coronary heart disease. Asztalos BF, Roheim PS, Milani RL, Lefevre M, McNamara JR, Horvath KV, Schaefer EJ, Arterioscler Thromb Vasc Biol 2000 20 2670 2676 10.1161/01.ATV.20.12.2670 11116070
43. Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patients. Asztalos BF, Horvath KV, McNamara JR, Roheim PS, Rubinstein JJ, Schaefer EJ, Atherosclerosis 2002 164 361 369 10.1016/S0021-9150(02)00149-1 12204809